ProKidney Financials

PROK

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows ProKidney (PROK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PROK FY2025 2026-05-15

ProKidney is still a cash-funded development business, with clinical spending far larger than its $893K of revenue.

In FY2025, cash ended higher at $108.5M than FY2024 even though operations still used $120.1M. With investing cash providing $104.0M and financing adding only $25.6M, the stronger cash balance does not mark self-funded operations; it reflects non-operating liquidity support.

R&D spending of $114.1M was still more than double SG&A of $51.8M, which says the cost base is built around advancing the program rather than supporting a revenue engine. Even with modest expense easing from FY2024, revenue remains too small to absorb fixed costs, so reported losses are mostly a consequence of development-stage economics.

Near-term liquidity looks far stronger than the income statement: current assets of $280.7M versus current liabilities of $30.7M suggest day-to-day obligations are covered. But negative equity of -$1.01B shows years of cash burn have accumulated faster than capital replenishment, leaving a balance sheet that is liquid now but not internally funded.

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of ProKidney's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

ProKidney has an operating margin of -18477.8%, meaning the company retains $-18478 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -241678.9% the prior year.

Leverage

ProKidney carries a low D/E ratio of -1.33, meaning only $-1.33 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 9.13, ProKidney holds $9.13 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While ProKidney generated -$120.1M in operating cash flow, capex of $15.2M consumed most of it, leaving -$135.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

1/9

ProKidney passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

1.74x

For every $1 of reported earnings, ProKidney generates $1.74 in operating cash flow (-$120.1M OCF vs -$69.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-41251.8x

ProKidney earns $-41251.8 in operating income for every $1 of interest expense (-$165.0M vs $4K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$893K

YoY+1075.0%

ProKidney generated $893K in revenue in fiscal year 2025. This represents an increase of 1075.0% from the prior year.

EBITDA

-$158.4M

YoY+11.1%

ProKidney's EBITDA was -$158.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.1% from the prior year.

Net Income

-$69.0M

YoY-12.7%

ProKidney reported -$69.0M in net income in fiscal year 2025. This represents a decrease of 12.7% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$135.3M

YoY+13.2%

ProKidney generated -$135.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 13.2% from the prior year.

Cash & Debt

$108.5M

YoY+9.5%

5Y CAGR+88.4%

ProKidney held $108.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

-18477.8%

YoY+223201.1pp

ProKidney's operating margin was -18477.8% in fiscal year 2025, reflecting core business profitability. This is up 223201.1 percentage points from the prior year.

Net Margin

-7725.2%

YoY+72782.7pp

ProKidney's net profit margin was -7725.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 72782.7 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$114.1M

YoY-10.6%

5Y CAGR+40.2%

ProKidney invested $114.1M in research and development in fiscal year 2025. This represents a decrease of 10.6% from the prior year.

Share Buybacks

ProKidney spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$15.2M

YoY-48.5%

5Y CAGR+22.7%

ProKidney invested $15.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 48.5% from the prior year.

PROK Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$893K+1075.0%	$76K	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$114.1M-10.6%	$127.7M+19.6%	$106.7M+30.0%	$82.1M+77.4%	$46.3M+119.8%	$21.0M
SG&A Expenses	$51.8M-7.7%	$56.1M+25.1%	$44.8M-36.8%	$70.9M+701.1%	$8.9M+48.0%	$6.0M
Operating Income	-$165.0M+10.2%	-$183.7M-21.2%	-$151.5M+1.0%	-$153.0M-177.6%	-$55.1M-103.9%	-$27.0M
Interest Expense	$4K-55.6%	$9K-25.0%	$12K-94.4%	$215K	$0	$0
Income Tax	$414K+169.2%	-$598K-110.0%	$6.0M+569.2%	$896K+2257.9%	$38K+116.4%	-$232K
Net Income	-$69.0M-12.7%	-$61.2M-72.5%	-$35.5M+76.1%	-$148.1M-168.6%	-$55.1M-106.2%	-$26.7M
EPS (Diluted)	N/A	N/A	N/A	$-0.23	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$226K+0.4%	$225K+3.7%	$217K-1.8%	$221K-3.9%	$230K	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.8M-0.9%	$34.2M+27.4%	$26.8M+3.6%	$25.9M-5.1%	$27.3M	N/A	$31.3M+6.3%	$29.4M
SG&A Expenses	$11.3M-1.1%	$11.4M-4.2%	$11.9M-15.0%	$14.0M-2.1%	$14.4M	N/A	$17.7M+29.8%	$13.7M
Operating Income	-$44.9M+1.0%	-$45.4M-17.7%	-$38.5M+2.9%	-$39.7M+4.1%	-$41.4M	N/A	-$49.0M-13.7%	-$43.1M
Interest Expense	$15K+1400.0%	$1K-50.0%	$2K+100.0%	$1K	$0	N/A	$2K-33.3%	$3K
Income Tax	$591K+137.3%	-$1.6M-383.0%	$560K-34.0%	$848K+43.5%	$591K	N/A	-$2.3M-4082.1%	-$56K
Net Income	-$20.0M-4.2%	-$19.2M-16.8%	-$16.5M+0.5%	-$16.6M+1.1%	-$16.7M	N/A	-$17.9M-43.2%	-$12.5M
EPS (Diluted)	$-0.14	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PROK Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$335.6M-23.9%	$441.1M+4.9%	$420.6M-18.8%	$518.0M+1185.4%	$40.3M	N/A
Current Assets	$280.7M-29.1%	$395.9M+5.8%	$374.1M-25.9%	$504.7M+1750.8%	$27.3M	N/A
Cash & Equivalents	$108.5M+9.5%	$99.1M+63.4%	$60.6M-87.6%	$490.3M+2284.7%	$20.6M+349.1%	$4.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3B-6.2%	$1.4B-5.8%	$1.5B-5.6%	$1.6B+11966.5%	$13.4M	N/A
Current Liabilities	$30.7M-15.1%	$36.2M+44.6%	$25.0M+130.3%	$10.9M-11.7%	$12.3M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.0B-1.6%	-$995.0M+9.8%	-$1.1B-0.6%	-$1.1B-4174.1%	$26.9M+172.9%	$9.9M
Retained Earnings	-$1.3B-5.7%	-$1.2B-5.4%	-$1.1B-3.2%	-$1.1B-583.6%	-$161.5M	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$292.8M-12.8%	$335.6M-4.6%	$351.6M-5.5%	$372.1M-8.4%	$406.1M-7.9%	$441.1M-7.1%	$474.8M-4.9%	$499.2M
Current Assets	$234.9M-16.3%	$280.7M-6.4%	$300.0M-7.5%	$324.4M-9.8%	$359.7M-9.1%	$395.9M-8.0%	$430.2M-4.5%	$450.3M
Cash & Equivalents	$101.9M-6.1%	$108.5M+13.9%	$95.3M+12.2%	$84.9M-13.2%	$97.8M-1.3%	$99.1M-8.3%	$108.1M-49.6%	$214.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3B-2.2%	$1.3B-0.9%	$1.4B-1.1%	$1.4B-2.1%	$1.4B-2.2%	$1.4B-1.3%	$1.5B-1.2%	$1.5B
Current Liabilities	$25.9M-15.6%	$30.7M+5.8%	$29.1M+2.8%	$28.3M-13.9%	$32.8M-9.4%	$36.2M+43.8%	$25.2M+22.3%	$20.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.0B-1.2%	-$1.0B-0.3%	-$1.0B-0.6%	-$1.0B-0.4%	-$998.6M-0.4%	-$995.0M-1.6%	-$979.7M-0.8%	-$972.4M
Retained Earnings	-$1.3B-1.6%	-$1.3B-1.5%	-$1.3B-1.3%	-$1.2B-1.4%	-$1.2B-1.4%	-$1.2B-1.8%	-$1.2B-1.5%	-$1.2B

PROK Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$120.1M+4.9%	-$126.4M-40.3%	-$90.1M-16.8%	-$77.1M-53.3%	-$50.3M-99.7%	-$25.2M
Capital Expenditures	$15.2M-48.5%	$29.5M-13.7%	$34.2M+1752.5%	$1.8M-64.4%	$5.2M-4.8%	$5.5M
Free Cash Flow	-$135.3M+13.2%	-$155.9M-25.4%	-$124.3M-57.4%	-$78.9M-42.2%	-$55.5M-81.1%	-$30.6M
Investing Cash Flow	$104.0M+409.3%	$20.4M+106.2%	-$330.0M-18886.4%	-$1.7M+66.5%	-$5.2M+4.9%	-$5.5M
Financing Cash Flow	$25.6M-82.3%	$144.4M+1612.0%	-$9.6M-101.7%	$548.5M+667.5%	$71.5M+257.5%	$20.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$9.5M	$0	$0	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$41.7M-28.2%	-$32.5M-22.2%	-$26.6M+15.3%	-$31.4M-6.2%	-$29.6M-22.4%	-$24.2M+17.3%	-$29.2M+23.6%	-$38.3M
Capital Expenditures	$3.8M-34.2%	$5.8M+10.7%	$5.2M+67.0%	$3.1M+174.2%	$1.1M-95.6%	$25.5M+961.1%	$2.4M+278.0%	$636K
Free Cash Flow	-$45.5M-18.8%	-$38.3M-20.4%	-$31.8M+7.9%	-$34.5M-12.4%	-$30.7M+38.2%	-$49.7M-57.0%	-$31.6M+18.7%	-$38.9M
Investing Cash Flow	$34.8M+24.0%	$28.1M-3.2%	$29.0M+56.3%	$18.6M-34.4%	$28.3M+87.6%	$15.1M+118.5%	-$81.6M-385.7%	$28.6M
Financing Cash Flow	$215K-98.8%	$17.6M+121.5%	$8.0M+56964.3%	-$14K-16.7%	-$12K-109.8%	$123K-97.2%	$4.5M-96.8%	$139.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PROK Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-18477.8%+223201.1pp	-241678.9%	N/A	N/A	N/A	N/A
Net Margin	-7725.2%+72782.7pp	-80507.9%	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-204.9%+66.3pp	-271.2%
Return on Assets	-20.6%-6.7pp	-13.9%-5.4pp	-8.4%+20.2pp	-28.6%+108.3pp	-136.8%	N/A
Current Ratio	9.13-1.8	10.93-4.0	14.94-31.5	46.42+44.2	2.21	N/A
Debt-to-Equity	-1.33+0.1	-1.44-0.1	-1.38+0.1	-1.47-2.0	0.50	N/A
FCF Margin	-15152.6%+189926.3pp	-205078.9%	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-19881.9%+283.0pp	-20164.9%-2405.0pp	-17759.9%+208.0pp	-17967.9%+26.9pp	-17994.8%	N/A	N/A	N/A
Net Margin	-8865.9%-318.8pp	-8547.1%-957.7pp	-7589.4%-99.8pp	-7489.6%-213.9pp	-7275.7%	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-6.8%-1.1pp	-5.7%-1.0pp	-4.7%-0.2pp	-4.5%-0.3pp	-4.1%	N/A	-3.8%-1.3pp	-2.5%
Current Ratio	9.06-0.1	9.13-1.2	10.32-1.2	11.48+0.5	10.96+0.0	10.93-6.2	17.09-4.8	21.87
Debt-to-Equity	-1.29+0.0	-1.33+0.0	-1.35+0.0	-1.37+0.0	-1.41+0.0	-1.44+0.0	-1.48+0.0	-1.51
FCF Margin	-20119.0%-3112.4pp	-17006.7%-2355.5pp	-14651.2%+972.4pp	-15623.5%-2264.0pp	-13359.6%	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.0B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Sarepta Therapeutics Inc SRPT

$2.0B

Dyne Therapeutics, Inc. DYN

$3.0B

Aurinia Pharmace AUPH

$2.0B

Ardelyx ARDX

$1.6B

Mesoblast MESO

$1.9B

Frequently Asked Questions

What is ProKidney's annual revenue?

ProKidney (PROK) reported $893K in total revenue for fiscal year 2025. This represents a 1075.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ProKidney's revenue growing?

ProKidney (PROK) revenue grew by 1075% year-over-year, from $76K to $893K in fiscal year 2025.

Is ProKidney profitable?

No, ProKidney (PROK) reported a net income of -$69.0M in fiscal year 2025, with a net profit margin of -7725.2%.

What is ProKidney's EBITDA?

ProKidney (PROK) had EBITDA of -$158.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ProKidney's operating margin?

ProKidney (PROK) had an operating margin of -18477.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is ProKidney's net profit margin?

ProKidney (PROK) had a net profit margin of -7725.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is ProKidney's free cash flow?

ProKidney (PROK) generated -$135.3M in free cash flow during fiscal year 2025. This represents a 13.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ProKidney's operating cash flow?

ProKidney (PROK) generated -$120.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ProKidney's total assets?

ProKidney (PROK) had $335.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ProKidney's capital expenditures?

ProKidney (PROK) invested $15.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ProKidney spend on research and development?

ProKidney (PROK) invested $114.1M in research and development during fiscal year 2025.

What is ProKidney's current ratio?

ProKidney (PROK) had a current ratio of 9.13 as of fiscal year 2025, which is generally considered healthy.

What is ProKidney's debt-to-equity ratio?

ProKidney (PROK) had a debt-to-equity ratio of -1.33 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ProKidney's return on assets (ROA)?

ProKidney (PROK) had a return on assets of -20.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ProKidney's cash runway?

Based on fiscal year 2025 data, ProKidney (PROK) had $108.5M in cash against an annual operating cash burn of $120.1M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is ProKidney's debt-to-equity ratio negative or unusual?

ProKidney (PROK) has negative shareholder equity of -$1.0B as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is ProKidney's Piotroski F-Score?

ProKidney (PROK) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ProKidney's earnings high quality?

ProKidney (PROK) has an earnings quality ratio of 1.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ProKidney cover its interest payments?

ProKidney (PROK) has an interest coverage ratio of -41251.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is ProKidney?

ProKidney (PROK) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.